Cargando...
Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis
BACKGROUND: Febuxostat is approved in the United States for the management of hyperuricemia in patients with gout. In November 2017 the FDA released a warning alert on a possible link between febuxostat and cardiovascular disease (CVD) reported in a single clinical trial. OBJECTIVE: To conduct a sys...
Gardado en:
| Publicado en: | Int J Rheumatol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Hindawi
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6378016/ https://ncbi.nlm.nih.gov/pubmed/30863448 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/1076189 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|